Selective Estrogen Receptor Modulators (SERM)

A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)

Also Known As:

Networked: 1938 relevant articles (174 outcomes, 308 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Jordan, V Craig: 33 articles (11/2021 - 01/2002)
2.	Komm, Barry S: 19 articles (01/2016 - 09/2005)
3.	Thatcher, Gregory R J: 16 articles (01/2017 - 10/2003)
4.	Jordan, V C: 14 articles (01/2007 - 01/2000)
5.	Bolton, Judy L: 13 articles (05/2014 - 10/2003)
6.	McDonnell, Donald P: 12 articles (01/2020 - 07/2002)
7.	Gennari, Luigi: 12 articles (04/2012 - 04/2004)
8.	Vogel, Victor G: 11 articles (01/2020 - 03/2004)
9.	Wickerham, D Lawrence: 11 articles (11/2017 - 01/2005)
10.	Ingle, James N: 9 articles (10/2017 - 08/2007)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 03/01/2012 - "The SERMs have good long-term safety, including protective effects against breast cancer. " 01/01/2021 - "CC is a selective estrogen receptor modulator, having promising therapeutic efficacy against breast cancer. " 09/14/2021 - "SERM treatment, albeit generally safe and effective, may increase diabetes risk with its long-term use in women with breast cancer. " 10/01/2002 - "This metabolic monitoring can thus serve to evaluate the efficacy of new selective estrogen receptor modulators and may be further extended to improve diagnosis and prognosis of breast cancer." 07/10/2021 - "This study performed a retrospective analysis of 308 SERMs-treated early breast cancer patients who were matched 1:1 based on propensity scores. "
2.	Neoplasms (Cancer) 01/01/2020 - "AIs may be more effective in patients with pS6K1 positive tumors, while SERM could be considered an alternative option for patients with pS6K1 negative tumors." 01/01/2022 - "Comparative differential cytotoxicity of clinically used SERMs in human cancer lines of different origin and its predictive molecular docking studies of key target genes involved in cancer progression and treatment responses." 01/01/2021 - "This study demonstrates the importance of the P1272S SNP in both the effect of SERMs on BMD and the development of tumor in the bone." 01/01/2008 - "It is clear from three randomised trials that SERMs prevent ERalpha+ tumors only in women at increased risk and at population risk of BC entered into these trials. " 06/01/2007 - "In all studies, average tumor volumes in SERM-treated animals declined over the course of treatment. "
3.	Osteoporosis 03/01/2010 - "This result may suggest that SERM is also effective for male osteoporosis." 05/31/2011 - "SERM improved BMD and endothelial function in elderly postmenopausal women with osteoporosis who had received HRT, and these effects were comparable to or slightly stronger than those of HRT. " 04/01/2010 - "To evaluate a Phase III trial of a new SERM, arzoxefine, for prevention of osteoporosis in younger postmenopausal women. " 08/22/2023 - "Patients without osteoporosis treatment had the highest prescription rate of SERM (31.48%), and those with osteoporosis treatment had a higher prescription rate of AIs (34.28%). " 07/12/2021 - "SERMs did not increase the risk of VTE compared to BPs in Koreans with osteoporosis. "
4.	Postmenopausal Osteoporosis 05/01/2010 - "Promising results have been observed with the targeted development of newer and more tissue-specific SERMs, many of which are under investigation for postmenopausal osteoporosis. " 03/01/2010 - "More precise molecular mechanisms of the effect of SERM, especially in tissue/cell type specificity, may help to investigate new SERM, which is more specific and effective to treat post-menopausal osteoporosis." 01/01/2007 - "Animal studies and early clinical studies suggest effects in the bone similar to other SERMs with prevention of postmenopausal bone loss. " 03/01/2012 - "Several selective estrogen receptor modulators are in clinical development for postmenopausal osteoporosis. " 02/01/2012 - "EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis."
5.	Leiomyoma (Uterine Fibroids) 01/01/2005 - "In light of therapeutic efficacy and few adverse effects, SERM and SPRM may hold promise as novel treatment modalities for leiomyoma. " 07/01/2000 - "Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma." 12/01/2001 - "This antagonist activity in the uterine myometrium suggests that SERMs may be useful in the treatment of uterine leiomyoma." 10/17/2012 - "Further studies are required to establish evidence of benefit of SERMs in treating women with uterine fibroids. " 10/17/2012 - "There is no consistent evidence from the limited number of studies that SERMs reduce the size of fibroids or improve clinical outcomes. "

Related Drugs and Biologics

1.	Selective Estrogen Receptor Modulators (SERM)
2.	Tamoxifen
3.	Raloxifene Hydrochloride (Evista)
4.	Estrogens (Estrogen)
5.	Aromatase Inhibitors
6.	Hormones (Hormone)
7.	Estrogen Receptors
8.	Diphosphonates (Bisphosphonates)
9.	Lasofoxifene
10.	bazedoxifene

Related Therapies and Procedures

1.	Therapeutics
2.	Chemoprevention
3.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
4.	Estrogen Replacement Therapy
5.	Contraception (Birth Control)